AbbVie ABBV Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.64B-14.0% | $4.23B+75.1% | $2.42B-36.3% | $3.79B-10.2% | $4.23B-1.9% | ||
| $989M+3.6% | $955M-0.7% | $962M+3.0% | $934M-4.0% | $973M+6.8% | ||
| —— | —— | —— | -$1.34B-23.5% | -$1.09B+24.9% | ||
| —— | —— | $1.27B— | —— | —— | ||
| $265M+12.3% | $236M-30.4% | $339M-15.9% | $403M+1.0% | $399M+25.1% | ||
| —— | —— | —— | —— | -$881M-598% | ||
| $21.22B+11.5% | $19.03B-8.8% | $20.86B+8.2% | $19.28B+17.6% | $16.4B-12.8% | ||
| $1.24B+2.5% | $1.21B+3.2% | $1.18B+12.6% | $1.04B+2.8% | $1.02B+4.3% | ||
| —— | —— | —— | —— | —— | ||
| -$6.48B+2.4% | -$6.64B+5.8% | -$7.05B+41.4% | -$12.05B-0.7% | -$11.97B+42.5% | ||
| $11.82B+1.4% | $11.66B+1.4% | $11.5B+1.4% | $11.34B+1.4% | $11.18B+1.4% | ||
| $1.51B+53.9% | $980M-26.6% | $1.34B-1.0% | $1.35B+0.2% | $1.35B-21.3% | ||
| —— | —— | —— | —— | —— | ||
| -$10.55B+17.1% | -$12.72B+17.5% | -$15.42B— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.22B+1,529% | -$295M+81.9% | -$1.63B+75.6% | -$6.66B+48.3% | -$12.89B-76.8% | ||
| —— | $3B+1.6% | $2.95B+1.6% | $2.91B+1.7% | $2.86B+1.7% | ||
| —— | —— | -$902M-235% | -$269M-28.7% | -$209M-141% | ||
| $42M+1,300% | $3M— | —— | —— | —— | ||
| $3.04B+6.0% | $2.87B+5.2% | $2.72B+7.8% | $2.53B+17.4% | $2.15B+7.9% | ||
| $7.33B-1.5% | $7.44B-1.5% | $7.55B0.0% | $7.55B0.0% | $7.55B-0.4% | ||
| $7.36B+13.4% | $6.5B+21.0% | $5.37B-9.8% | $5.95B+28.5% | $4.63B+22.8% | ||
| $769M+0.9% | $762M-0.4% | $765M+0.1% | $764M+0.3% | $762M-0.3% | ||
| —— | —— | -$3.21B-14.7% | -$2.8B+14.1% | -$3.26B0.0% | ||
| —— | —— | —— | —— | —— | ||
| $42M+1,300% | $3M— | —— | —— | —— | ||
| $110M+279% | $29M+117% | -$169M+32.1% | -$249M-6.9% | -$233M-23.3% | ||
| $5.17B-1.3% | $5.24B-10.8% | $5.87B+79.7% | $3.27B+3.1% | $3.17B+4.8% | ||
| $4.8B+71.5% | $2.8B— | —— | —— | —— | ||
| —— | —— | —— | —— | $100M+75.4% | ||
| —— | —— | —— | —— | $1.59B— | ||
| $3.77B-44.5% | $6.8B-45.8% | $12.55B-3.0% | $12.95B+3.3% | $12.54B+30.4% | ||
| —— | —— | —— | —— | —— | ||
| $19.98B+12.1% | $17.82B-9.5% | $19.68B+7.9% | $18.24B+18.6% | $15.39B-13.7% | ||
| $19.98B+12.1% | $17.82B-9.5% | $19.68B+7.9% | $18.24B+18.6% | $15.39B-13.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbbVie generate?
- AbbVie (ABBV) generated $21.2B in operating cash flow over the trailing twelve months.
- What is AbbVie's free cash flow?
- After $1.2B of capital expenditures, AbbVie's free cash flow was $20.0B over the trailing twelve months, up 29.9% year over year.
- Where does AbbVie's cash flow data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
